Bayer said China's NMPA approved sevabertinib tablets as monotherapy for adults with unresectable locally advanced or metastatic NSCLC harboring activating HER2 (ERBB2) mutations after at least one prior systemic therapy. The oral small-molecule TKI had previously received Breakthrough Therapy Designation from the CDE, and its application was included in priority review. The approval expands options for a biomarker-defined subgroup with limited targeted treatments.
According to the article, lung cancer accounted for 2.48 million new cases worldwide in 2022, or 12.4% of all incident cancers, while mainland China records about 1.06 million new cases each year. NSCLC represents more than 85% of lung cancers, and activating HER2 mutations occur in 2% to 4% of advanced NSCLC, with a reported incidence of 4.3% in Chinese patients. Bayer said sevabertinib inhibits mutant HER2, including exon 20 insertions and point mutations, and shows high selectivity for mutant versus wild-type EGFR.
The approval was supported by the open-label, multicenter phase I/II SOHO-01 study in advanced HER2-mutant NSCLC after disease progression on one or more prior systemic regimens and without prior HER2-targeted TKI therapy. In patients without previous HER2-targeted ADC exposure, objective response rate was 64%, including 2.5% complete responses and 62% partial responses, with a median duration of response of 9.2 months (95% CI, 6.3-15.0; n=52). In patients previously treated with HER2-targeted ADCs, objective response rate was 38%, including 5.5% complete responses and 33% partial responses, and median duration of response was 7 months. Bayer said safety was manageable and consistent with earlier reports.